Diagnosis and management of maturity onset diabetes of the young (MODY)

@article{Thanabalasingham2011DiagnosisAM,
  title={Diagnosis and management of maturity onset diabetes of the young (MODY)},
  author={Gaya Thanabalasingham and Katharine R. Owen},
  journal={BMJ : British Medical Journal},
  year={2011},
  volume={343}
}
#### Summary points Maturity onset diabetes of the young (MODY) comprises a heterogeneous group of monogenic disorders characterised by β cell dysfunction. It is estimated to be the underlying cause of diabetes in 1-2% of patients diagnosed with diabetes, but prevalence estimates will not be accurate until large population screening studies are performed.1 It is important to distinguish MODY from type 1 and type 2 diabetes because optimal treatments are different. Furthermore, first degree… 
Diagnosis and Treatment of MODY: An Updated Mini Review
TLDR
This review serves to explore MODY subtypes, diagnosis, and treatment, and increase awareness of MODY incidence to allow for more effective therapeutic management and treatment strategies that are distinct from those used for type 1 and type 2 diabetes.
Maturity onset diabetes of the young: clinical characteristics, diagnosis and management.
TLDR
Raising awareness about MODY and making the diagnosis more accessible will improve prognostication and management of these patients and their relatives.
MODY Probability Ratios in Patients Diagnosed with Type 2 Diabetes Mellitus at a Young Age
TLDR
It has been reported that MODY risk calculated by MPC may yield different results in different populations, and the results of this study showed that 15% of young-onset diabetes patients had an MPC score above 20 percent.
Maturity-onset diabetes of the young (MODY): an update
TLDR
The main clinical and laboratory characteristics of the common and rarer causes of MODY are summarized.
Frequency and genetic spectrum of maturity-onset diabetes of the young (MODY) in southern New Zealand
TLDR
These families highlight the features of three of the more common MODY subtypes, including two with novel mutations, one of which segregates in a kindred that is strongly affected by both MODY and classic autoimmune mediated diabetes.
Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management.
Maturity onset diabetes of the young
TLDR
Basic information is presented about this rare, but rather important, genetic disorder that is linked to diabetes in younger people and awareness of this condition among primary care physicians should improve diagnosis.
Maturity onset diabetes of the young: Seek and you will find.
TLDR
It is shown that a doctor's clinical eye and taking the time for a detailed family history may be equal to, or even better than, the best prediction rule in finding patients in whom further genetic testing for possible MODY is warranted.
Maturity onset diabetes of young type 2 due to a novel de novo GKC mutation.
TLDR
A 13-year-old, healthy and non-obese girl was admitted for investigation of recurrent hyperglycemia episodes and a novel missense heterozygous mutation in exon 5 of GCK gene c.509G > T (p.Gly170Val) was identified, establishing the diagnosis of MODY type 2.
Maturity-onset diabetes of the young (MODY)-related genetic variants in a Turkish patient cohort with early-onset diabetes: a cross-sectional study
TLDR
It is presented that diabetic patients below 35 age, without low C-peptide levels and any positivity for beta-cell autoimmunity markers, must be screened for MODY gene panel for diagnosis and genetic counseling.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Maturity-onset diabetes of the young (MODY): how many cases are we missing?
TLDR
The regional distribution of confirmed MODY cases in the UK is compared and the minimum prevalence is estimated to be 108 cases per million, assuming >80% of MODY is not diagnosed by molecular testing.
Genetic testing in maturity onset diabetes of the young (MODY): a new challenge for the diabetic clinic
TLDR
The genetics of MODY is reviewed and experiences of genetic testing in diabetes to date are reviewed and what can be learnt from geneticTesting in other diseases is considered and it is proposed that recent classifications of diabetes ‘genetic disorders of beta cell function’ are recognised as separate disorders.
Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene.
TLDR
The phenotypes of a large series of MODY3 patients are described and parameters that may improve its diagnosis are reassessed to improve the pick-up rate of MODy3 diagnosis.
Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young
TLDR
Best practice guidelines have been established for monogenic forms of diabetes caused by mutations in the GCK, HNF1A and HNF4A genes, which include both diagnostic and predictive genetic tests and interpretation of the results.
Assessment of High-Sensitivity C-Reactive Protein Levels as Diagnostic Discriminator of Maturity-Onset Diabetes of the Young Due to HNF1A Mutations
TLDR
Serum hs-CRP levels are markedly lower in HNF1A-MODY than in other forms of diabetes, and has potential as a widely available, cost-effective screening test to support more precise targeting of MODY diagnostic testing.
Mild familial diabetes with dominant inheritance.
TLDR
Three families have been described in which diabetes, although usually diagnosed in the teens or early 20s, is mild and does not progress to insulin dependence even over a period of 40 years, which provides evidence of the genetic heterogeneity of diabetes mellitus.
Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents
TLDR
The aetiological diagnosis in asymptomatic hyperglycaemic children and adolescents is a clue to introducing an early and effective therapy or, in MODY2, to preventing any future extensive re-investigations.
High-Sensitivity CRP Discriminates HNF1A-MODY From Other Subtypes of Diabetes
OBJECTIVE Maturity-onset diabetes of the young (MODY) as a result of mutations in hepatocyte nuclear factor 1-α (HNF1A) is often misdiagnosed as type 1 diabetes or type 2 diabetes. Recent work has
Phenotypical aspects of maturity‐onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database
TLDR
The objective is to analyse and compare clinical characteristics in young patients with maturity‐onset diabetes of the young and Type 2 diabetes mellitus and to propose treatment regimens suitable for this condition.
A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin‐treated patients
TLDR
This work aimed to assess if patients do change from insulin to sulphonylurea treatment when HNF1A diabetes is confirmed and the impact of this treatment change on long‐term glycaemic control.
...
1
2
3
4
...